Combined MRI and 31P-MRS Investigations of the ACTA1(H40Y) Mouse Model of Nemaline Myopathy Show Impaired Muscle Function and Altered Energy Metabolism

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Gineste, Charlotte ^a   Le Fur, Yann ^a   Vilmen, Christophe ^a   Le Troter, Arnaud ^a   Pecchi, Emilie ^a   Cozzone, Patrick J ^a   Hardeman, Edna C ^b   Bendahan, David ^a   Gondin, Julien ^a  

^a University of Aix Marseille   (France)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ 1; BIOLOGICAL MARKER; ACTIN;

ALPHA ACTININ 1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENERGY COST; ENERGY METABOLISM; FAT MASS; FEMALE; GASTROCNEMIUS MUSCLE; HINDLIMB; MECHANICAL STIMULATION; MOUSE; MUSCLE CONTRACTION; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE WEAKNESS; MUTATIONAL ANALYSIS; NEMALINE MYOPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; ANIMAL; GENETICS; METABOLISM; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

MUS;

ACTINS; ANIMALS; ENERGY METABOLISM; FEMALE; MAGNETIC RESONANCE IMAGING; MICE; MICE, MUTANT STRAINS; MUSCLE, SKELETAL; MYOPATHIES, NEMALINE;

EID: 84876171888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061517     Document Type: Article

References (55)

1. Schnell C, Kan A, North KN, (2000) 'An artefact gone awry': identification of the first case of nemaline myopathy by Dr R.D.K. Reye. Neuromuscul Disord. 10: 307-312.
2. North KN, Laing NG, Wallgren-Pettersson C, (1997) Nemaline myopathy: current concepts. The ENMC International Consortium and Nemaline Myopathy. J Med Genet. 34: 705-713.
3. Wang CH, Dowling JJ, North K, Schroth MK, Sejersen T, et al. (2012) Consensus statement on standard of care for congenital myopathies. J Child Neurol. 27: 363-382.
4. Sanoudou D, Beggs AH, (2001) Clinical and genetic heterogeneity in nemaline myopathy-a disease of skeletal muscle thin filaments. Trends Mol Med. 7: 362-368.
5. Wallgren-Pettersson C, Sewry CA, Nowak KJ, Laing NG, (2011) Nemaline myopathies. Semin Pediatr Neurol. 18: 230-238.
6. Agrawal PB, Strickland CD, Midgett C, Morales A, Newburger DE, et al. (2004) Heterogeneity of nemaline myopathy cases with skeletal muscle alpha-actin gene mutations. Ann Neurol. 56: 86-96.
7. Wallgren-Pettersson C, Pelin K, Nowak KJ, Muntoni F, Romero NB, et al. (2004) Genotype-phenotype correlations in nemaline myopathy caused by mutations in the genes for nebulin and skeletal muscle alpha-actin. Neuromuscul Disord. 14: 461-470.
8. Clarkson E, Costa CF, Machesky LM, (2004) Congenital myopathies: diseases of the actin cytoskeleton. J Pathol. 204: 407-417.
9. Laing NG, Dye DE, Wallgren-Pettersson C, Richard G, Monnier N, et al. (2009) Mutations and polymorphisms of the skeletal muscle alpha-actin gene (ACTA1). Hum Mutat. 30: 1267-1277.
10. Ravenscroft G, Wilmshurst JM, Pillay K, Sivadorai P, Wallefeld W, et al. (2010) A novel ACTA1 mutation resulting in a severe congenital myopathy with nemaline bodies, intranuclear rods and type I fibre predominance. Neuromuscul Disord. 21: 31-36.
11. Jungbluth H, Sewry CA, Brown SC, Nowak KJ, Laing NG, et al. (2001) Mild phenotype of nemaline myopathy with sleep hypoventilation due to a mutation in the skeletal muscle alpha-actin (ACTA1) gene. Neuromuscul Disord. 11: 35-40.
12. Marston S, Mirza M, Abdulrazzak H, Sewry C, (2004) Functional characterisation of a mutant actin (Met132Val) from a patient with nemaline myopathy. Neuromuscul Disord. 14: 167-174.
13. Nguyen MA, Hardeman EC, (2008) Mouse models for thin filament disease. Adv Exp Med Biol. 642: 66-77.
14. Crawford K, Flick R, Close L, Shelly D, Paul R, et al. (2002) Mice lacking skeletal muscle actin show reduced muscle strength and growth deficits and die during the neonatal period. Mol Cell Biol. 22: 5887-5896.
15. Ravenscroft G, Jackaman C, Bringans S, Papadimitriou JM, Griffiths LM, et al. (2011) Mouse models of dominant ACTA1 disease recapitulate human disease and provide insight into therapies. Brain. 134: 1101-1115.
16. Nguyen MA, Joya JE, Kee AJ, Domazetovska A, Yang N, et al. (2011) Hypertrophy and dietary tyrosine ameliorate the phenotypes of a mouse model of severe nemaline myopathy. Brain. 134: 3516-3529.
17. Jungbluth H, Sewry CA, Counsell S, Allsop J, Chattopadhyay A, et al. (2004) Magnetic resonance imaging of muscle in nemaline myopathy. Neuromuscul Disord. 14: 779-784.
18. Walter G, Cordier L, Bloy D, Sweeney HL, (2005) Noninvasive monitoring of gene correction in dystrophic muscle. Magn Reson Med. 54: 1369-1376.
19. Lawlor MW, Ottenheijm CA, Lehtokari VL, Cho K, Pelin K, et al. (2011) Novel mutations in NEB cause abnormal nebulin expression and markedly impaired muscle force generation in severe nemaline myopathy. Skelet Muscle. 1: 23.
20. Gordon AM, Homsher E, Regnier M, (2000) Regulation of contraction in striated muscle. Physiol Rev. 80: 853-924.
21. Ochala J, Li M, Ohlsson M, Oldfors A, Larsson L, (2008) Defective regulation of contractile function in muscle fibres carrying an E41K beta-tropomyosin mutation. J Physiol. 586: 2993-3004.
22. Ottenheijm CA, Lawlor MW, Stienen GJ, Granzier H, Beggs AH, (2011) Changes in cross-bridge cycling underlie muscle weakness in patients with tropomyosin 3-based myopathy. Hum Mol Genet. 20: 2015-2025.
23. Sanoudou D, Haslett JN, Kho AT, Guo S, Gazda HT, et al. (2003) Expression profiling reveals altered satellite cell numbers and glycolytic enzyme transcription in nemaline myopathy muscle. Proc Natl Acad Sci U S A. 100: 4666-4671.
24. Giannesini B, Cozzone PJ, Bendahan D, (2004) In vivo MR investigation of skeletal muscle function in small animals. Magma. 17: 210-218.
25. Bendahan D, Mattei JP, Kozak-Ribbens G, Cozzone PJ, (2002) [Non invasive investigation of muscle diseases using 31P magnetic resonance spectroscopy: potential in clinical applications]. Rev Neurol (Paris). 158: 527-540.
26. Henriksen O, (1994) MR spectroscopy in clinical research. Acta Radiol. 35: 96-116.
27. Wary C, Naulet T, Thibaud JL, Monnet A, Blot S, et al. (2012) Splitting of Pi and other (31)P NMR anomalies of skeletal muscle metabolites in canine muscular dystrophy. NMR Biomed. 25: 1160-1169.
28. Younkin DP, Berman P, Sladky J, Chee C, Bank W, et al. (1987) 31P NMR studies in Duchenne muscular dystrophy: age-related metabolic changes. Neurology. 37: 165-169.
29. Torriani M, Townsend E, Thomas BJ, Bredella MA, Ghomi RH, et al. (2012) Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study. Skeletal Radiol. 41: 437-445.
30. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, et al. (2000) Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques. 29: 52, 54.
31. Giannesini B, Vilmen C, Le Fur Y, Dalmasso C, Cozzone PJ, et al. (2010) A strictly noninvasive MR setup dedicated to longitudinal studies of mechanical performance, bioenergetics, anatomy, and muscle recruitment in contracting mouse skeletal muscle. Magn Reson Med. 64: 262-270.
32. Positano V, Christiansen T, Santarelli MF, Ringgaard S, Landini L, et al. (2009) Accurate segmentation of subcutaneous and intermuscular adipose tissue from MR images of the thigh. J Magn Reson Imaging. 29: 677-684.
33. Le Fur Y, Nicoli F, Guye M, Confort-Gouny S, Cozzone PJ, et al. (2010) Grid-free interactive and automated data processing for MR chemical shift imaging data. Magma. 23: 23-30.
34. Moon RB, Richards JH, (1973) Determination of intracellular pH by 31P magnetic resonance. J Biol Chem. 248: 7276-7278.
35. Quijano-Roy S, Carlier RY, Fischer D, (2011) Muscle imaging in congenital myopathies. Semin Pediatr Neurol. 18: 221-229.
36. Cole MA, Rafael JA, Taylor DJ, Lodi R, Davies KE, et al. (2002) A quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin. Neuromuscul Disord. 12: 247-257.
37. Charvet C, Houbron C, Parlakian A, Giordani J, Lahoute C, et al. (2006) New role for serum response factor in postnatal skeletal muscle growth and regeneration via the interleukin 4 and insulin-like growth factor 1 pathways. Mol Cell Biol. 26: 6664-6674.
38. Visegrady B, Machesky LM, (2010) Myopathy-causing actin mutations promote defects in serum-response factor signalling. Biochem J. 427: 41-48.
39. Ottenheijm CA, Hooijman P, Dechene ET, Stienen GJ, Beggs AH, et al. (2010) Altered myofilament function depresses force generation in Patients with nebulin-based nemaline myopathy (nem2). J Struct Biol. 170: 334-343.
40. Ochala J, (2010) Ca2+ sensitizers: An emerging class of agents for counterbalancing weakness in skeletal muscle diseases? Neuromuscul Disord. 20: 98-101.
41. Nunes PM, van de Weijer T, Veltien A, Arnts H, Hesselink MK, et al. (2012) Increased intramyocellular lipids but unaltered in vivo mitochondrial oxidative phosphorylation in skeletal muscle of adipose triglyceride lipase-deficient mice. Am J Physiol Endocrinol Metab. 303: E71-81.
42. Lanza IR, Bhagra S, Nair KS, Port JD, (2011) Measurement of human skeletal muscle oxidative capacity by 31P-MR spectroscopy: a cross-validation with in vitro measurements. J Magn Reson Imaging. 34: 1143-1150.
43. Baligand C, Wary C, Menard JC, Giacomini E, Hogrel JY, et al. (2011) Measuring perfusion and bioenergetics simultaneously in mouse skeletal muscle: a multiparametric functional-NMR approach. NMR Biomed. 24: 281-290.
44. Gineste C, De Winter JM, Kohl C, Witt CC, Giannesini B, et al. (2013) In vivo and in vitro investigations of heterozygous nebulin knock-out mice disclose a mild skeletal muscle phenotype. Neuromuscul Disord.
45. Liu M, Walter GA, Pathare NC, Forster RE, Vandenborne K, (2007) A quantitative study of bioenergetics in skeletal muscle lacking carbonic anhydrase III using 31P magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 104: 371-376.
46. Nowak KJ, Wattanasirichaigoon D, Goebel HH, Wilce M, Pelin K, et al. (1999) Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet. 23: 208-212.
47. Sparrow JC, Nowak KJ, Durling HJ, Beggs AH, Wallgren-Pettersson C, et al. (2003) Muscle disease caused by mutations in the skeletal muscle alpha-actin gene (ACTA1). Neuromuscul Disord. 13: 519-531.
48. Bang ML, Caremani M, Brunello E, Littlefield R, Lieber RL, et al. (2009) Nebulin plays a direct role in promoting strong actin-myosin interactions. Faseb J. 23: 4117-4125.
49. Ochala J, Ravenscroft G, Laing NG, Nowak KJ, (2012) Nemaline Myopathy-Related Skeletal Muscle alpha-Actin (ACTA1) Mutation, Asp286Gly, Prevents Proper Strong Myosin Binding and Triggers Muscle Weakness. PLoS One. 7: e45923.
50. Achten E, Van Cauteren M, Willem R, Luypaert R, Malaisse WJ, et al. (1990) 31P-NMR spectroscopy and the metabolic properties of different muscle fibers. J Appl Physiol. 68: 644-649.
51. Park JH, Brown RL, Park CR, McCully K, Cohn M, et al. (1987) Functional pools of oxidative and glycolytic fibers in human muscle observed by 31P magnetic resonance spectroscopy during exercise. Proc Natl Acad Sci U S A. 84: 8976-8980.
52. Barclay CJ, Constable JK, Gibbs CL, (1993) Energetics of fast- and slow-twitch muscles of the mouse. J Physiol. 472: 61-80.
53. D'Antona G, Lanfranconi F, Pellegrino MA, Brocca L, Adami R, et al. (2006) Skeletal muscle hypertrophy and structure and function of skeletal muscle fibres in male body builders. J Physiol. 570: 611-627.
54. Gondin J, Guette M, Jubeau M, Ballay Y, Martin A, (2006) Central and peripheral contributions to fatigue after electrostimulation training. Med Sci Sports Exerc. 38: 1147-1156.
55. Hunter SK, Enoka RM, (2001) Sex differences in the fatigability of arm muscles depends on absolute force during isometric contractions. J Appl Physiol. 91: 2686-2694.